Designed variants of ACE2-Fc that decouple anti-SARS-CoV-2 activities from unwanted cardiovascular effects.
Angiotensin-converting enzyme 2 (ACE2) is the entry receptor for SARS-CoV-2, and recombinant ACE2 decoys are being evaluated as new antiviral therapies. We designed and tested an antibody-like ACE2-Fc fusion protein, which has the benefit of long pharmacological half-life and the potential to facilitate immune clearance of the virus. Out of a concern that the intrinsic catalytic activity of ACE2 may unintentionally alter the balance of its hormonal substrates and cause adverse cardiovascular effects in treatment, we performed a mutagenesis screening for inactivating the enzyme. Three mutants, R273A, H378A and E402A, completely lost their enzymatic activity for either surrogate or physiological substrates. All of them remained capable of binding SARS-CoV-2 and could suppress the transduction of a pseudotyped virus in cell culture. This study established new ACE2-Fc candidates as antiviral treatment for SARS-CoV-2 without potentially harmful side effects from ACE2's catalytic actions toward its vasoactive substrates.
['Liu|Pan|P|', 'Xie|Xinfang|X|', 'Gao|Li|L|', 'Jin|Jing|J|']
D019943:Amino Acid Substitution D000085962:Angiotensin-Converting Enzyme 2 D000818:Animals D000086382:COVID-19 D002460:Cell Line D005260:Female D006801:Humans D007141:Immunoglobulin Fc Fragments D051379:Mice D008807:Mice, Inbred BALB C D020125:Mutation, Missense D011993:Recombinant Fusion Proteins D000086402:SARS-CoV-2
ACE2-Fc SARS-CoV-2 Mutagenesis COVID-19